查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1922444

日本心臟生物标记市场报告：按类型、检测施行地点、应用和地区划分（2026-2034年）

Japan Cardiac Biomarkers Market Report by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Brain Natriuretic Peptide or NT-proBNP, Ischemia Modified Albumin, and Others), Location of Testing, Application, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 121 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2025年，日本心臟生物标记市场规模达7.311亿美元。 IMARC集团预测，到2034年，该市场规模将达到13.93亿美元，2026年至2034年的复合年增长率（CAGR）为7.43%。心臟病、中风和心臟衰竭等心血管疾病的日益增多，推动了对心臟生物标记的需求，使其能够用于早期检测、风险评估和病患监测，从而扩大了市场规模。

心臟生物标记是指在心臟相关疾病发生时释放到血液中的蛋白质或分子。它们在诊断和监测各种心臟疾病方面发挥着重要作用。典型的心臟生物标记包括肌钙蛋白、肌酸激酶-MB (CK-MB) 和 B 型钠尿肽 (BNP)。肌钙蛋白是心肌损伤的高度特异性指标，对于诊断心肌梗塞至关重要。 CK-MB 是另一种在心肌损伤时升高的酵素。而 BNP 则有助于评估心臟衰竭及其严重程度。透过血液检测测量心臟生物标记物，医护人员可以检测和评估心臟问题，确定损伤程度，并制定合适的治疗方案。这些生物标记能够提供有关心臟整体健康状况的重要信息，并指南医疗干预以改善患者预后。定期监测心臟生物标记对于控制心臟疾病和预防併发症至关重要。

日本心臟生物标记市场趋势：

由于几个关键因素，日本心臟生物标记市场预计将显着成长。首先，包括冠状动脉疾病和心臟衰竭在内的心血管疾病盛行率不断上升，显着推动了对心臟生物标记检测的需求。此外，该地区人口老化也是一个重要的驱动因素。老年族群罹患心臟相关疾病的风险更高，因此对心臟生物标记诊断的需求持续存在。此外，医疗技术的进步和高灵敏度心臟生物标记检测的广泛应用提高了心臟疾病检测的准确性和效率。这不仅改善了患者的治疗效果，也促使医疗机构将这些检测纳入常规临床实务。此外，医护人员和患者对早期发现和预防心臟病重要性的认识不断提高，也导致了检测率的上升。对预防医学和心臟健康主动监测的日益重视正在推动心臟生物标记市场的发展。最后，政府对心血管研究和诊断工具的支持措施和资金投入也促进了市场扩张。总而言之，这些驱动因素共同为心臟生物标记市场在不久的将来持续成长创造了有利环境。

本报告解答的关键问题

  • 日本心臟生物标记市场目前发展状况如何？未来几年又将如何发展？
  • 新冠疫情对日本心臟生物标记市场产生了哪些影响？
  • 日本心臟生物标记市场按类型是如何分類的？
  • 日本心臟生物标记市场依检测施行地点分類的组成是怎样的？
  • 日本心臟生物标记市场按应用领域分類的组成是怎样的？
  • 请介绍日本心臟生物标记市场价值链的各个环节。
  • 日本心臟生物标记市场的主要驱动因素和挑战是什么？
  • 日本心臟生物标记市场的结构是怎么样的？主要参与者有哪些？
  • 日本心臟生物标记市场竞争有多激烈？

目录

第一章：序言

第二章：调查范围与调查方法

  • 调查目标
  • 相关利益者
  • 数据来源
  • 市场估值
  • 调查方法

第三章执行摘要

第四章：日本心臟生物标记市场－简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争资讯

第五章 日本心臟生物标记市场概述

  • 过去和当前的市场趋势（2020-2025）
  • 市场预测（2026-2034）

第六章：日本心臟生物标记市场－按类型细分

  • 肌钙蛋白（T 和 I）
  • 心肌肌酸激酶（CK-MB）
  • 肌红蛋白
  • 脑钠肽（BNP）或NT-proBNP
  • 缺血修饰白蛋白（IMA）
  • 其他的

第七章：日本心臟生物标记市场－依检测地点划分

  • 检查室检测
  • 就地检验

第八章：日本心臟生物标记市场－按应用领域细分

  • 心肌梗塞
  • 郁血性心臟衰竭
  • 急性冠状动脉症候群
  • 动脉粥状硬化
  • 其他的

第九章：日本心臟生物标记市场：按地区划分

  • 关东地区
  • 关西、近畿地区
  • 中部地区
  • 九州和冲绳地区
  • 东北部地区
  • 中国地区
  • 北海道地区
  • 四国地区

第十章：日本心臟生物标记市场的竞争格局

  • 概述
  • 市场结构
  • 市场公司定位
  • 关键成功策略
  • 竞争对手仪錶板
  • 企业估值象限

第十一章主要企业概况

第十二章：日本心臟生物标记市场：产业分析

  • 驱动因素、限制因素和机会
  • 波特五力分析
  • 价值链分析

第十三章附录

简介目录
Product Code: SR112026A19462

Japan cardiac biomarkers market size reached USD 731.1 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 1,393.0 Million by 2034 , exhibiting a growth rate (CAGR) of 7.43% during 2026-2034 . The increasing prevalence of cardiovascular diseases such as heart attacks, strokes, and heart failure, that require cardiac biomarkers for early detection, risk assessment, and monitoring of patients, is driving the market.

Access the full market insights report Request Sample

Cardiac biomarkers are proteins or molecules released into the bloodstream in response to heart-related conditions. They play a crucial role in diagnosing and monitoring various heart disorders. Common cardiac biomarkers include troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP). Troponins are highly specific indicators of heart muscle damage and are essential in diagnosing heart attacks. CK-MB is another enzyme that rises in response to heart muscle injury. BNP, on the other hand, helps assess heart failure and its severity. Measuring cardiac biomarkers through blood tests allows healthcare professionals to detect and evaluate heart problems, determine the extent of damage, and formulate appropriate treatment plans. These biomarkers provide valuable insights into the overall health of the heart and help guide medical interventions to improve patient outcomes. Regular monitoring of cardiac biomarkers is essential in managing heart conditions and preventing complications.

JAPAN CARDIAC BIOMARKERS MARKET TRENDS:

The cardiac biomarkers market in Japan is poised for substantial growth, driven by several key factors. Firstly, the escalating prevalence of cardiovascular diseases, including coronary artery disease and heart failure, has significantly increased the demand for cardiac biomarker testing. Additionally, the aging regional population is a major driver, as older individuals are at higher risk of cardiac-related issues, creating a sustained need for cardiac biomarker diagnostics. Moreover, advancements in medical technology and the increasing adoption of high-sensitivity cardiac biomarker assays have enhanced the accuracy and efficiency of cardiac disease detection. This has not only improved patient outcomes but also encouraged healthcare providers to incorporate these tests into their routine clinical practices. Furthermore, the growing awareness among both healthcare professionals and patients regarding the importance of early cardiac disease detection and prevention has led to increased testing rates. The emphasis on preventive healthcare and proactive monitoring of cardiac health has bolstered the cardiac biomarkers market. Lastly, supportive government initiatives and funding for cardiovascular research and diagnostic tools have fueled market expansion. Overall, these drivers converge to create a favorable landscape for the cardiac biomarkers market's sustained growth in the foreseeable future.

JAPAN CARDIAC BIOMARKERS MARKET SEGMENTATION:

Type Insights:

  • To get detailed segment analysis of this market Request Sample
  • Troponins (T and I)
  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia Modified Albumin (IMA)
  • Others
  • Troponins (T and I)
  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia Modified Albumin (IMA)
  • Others

Location of Testing Insights:

  • Laboratory Testing
  • Point of Care Testing
  • Laboratory Testing
  • Point of Care Testing

Application Insights:

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others

Regional Insights:

  • To get detailed regional analysis of this market Request Sample
  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

  • KEY QUESTIONS ANSWERED IN THIS REPORT
  • How has the Japan cardiac biomarkers market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan cardiac biomarkers market?
  • What is the breakup of the Japan cardiac biomarkers market on the basis of type?
  • What is the breakup of the Japan cardiac biomarkers market on the basis of location of testing?
  • What is the breakup of the Japan cardiac biomarkers market on the basis of application?
  • What are the various stages in the value chain of the Japan cardiac biomarkers market?
  • What are the key driving factors and challenges in the Japan cardiac biomarkers?
  • What is the structure of the Japan cardiac biomarkers market and who are the key players?
  • What is the degree of competition in the Japan cardiac biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cardiac Biomarkers Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Cardiac Biomarkers Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Cardiac Biomarkers Market - Breakup by Type

  • 6.1 Troponins (T and I)
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Forecast (2026-2034)
  • 6.2 Myocardial Muscle Creatine Kinase (CK-MB)
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Forecast (2026-2034)
  • 6.3 Myoglobin
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2020-2025)
    • 6.3.3 Market Forecast (2026-2034)
  • 6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2020-2025)
    • 6.4.3 Market Forecast (2026-2034)
  • 6.5 Ischemia Modified Albumin (IMA)
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2020-2025)
    • 6.5.3 Market Forecast (2026-2034)
  • 6.6 Others
    • 6.6.1 Historical and Current Market Trends (2020-2025)
    • 6.6.2 Market Forecast (2026-2034)

7 Japan Cardiac Biomarkers Market - Breakup by Location of Testing

  • 7.1 Laboratory Testing
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Point of Care Testing
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)

8 Japan Cardiac Biomarkers Market - Breakup by Application

  • 8.1 Myocardial Infarction
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Forecast (2026-2034)
  • 8.2 Congestive Heart Failure
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Forecast (2026-2034)
  • 8.3 Acute Coronary Syndrome
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2020-2025)
    • 8.3.3 Market Forecast (2026-2034)
  • 8.4 Atherosclerosis
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2020-2025)
    • 8.4.3 Market Forecast (2026-2034)
  • 8.5 Others
    • 8.5.1 Historical and Current Market Trends (2020-2025)
    • 8.5.2 Market Forecast (2026-2034)

9 Japan Cardiac Biomarkers Market - Breakup by Region

  • 9.1 Kanto Region
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2020-2025)
    • 9.1.3 Market Breakup by Type
    • 9.1.4 Market Breakup by Location of Testing
    • 9.1.5 Market Breakup by Application
    • 9.1.6 Key Players
    • 9.1.7 Market Forecast (2026-2034)
  • 9.2 Kansai/Kinki Region
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2020-2025)
    • 9.2.3 Market Breakup by Type
    • 9.2.4 Market Breakup by Location of Testing
    • 9.2.5 Market Breakup by Application
    • 9.2.6 Key Players
    • 9.2.7 Market Forecast (2026-2034)
  • 9.3 Central/ Chubu Region
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2020-2025)
    • 9.3.3 Market Breakup by Type
    • 9.3.4 Market Breakup by Location of Testing
    • 9.3.5 Market Breakup by Application
    • 9.3.6 Key Players
    • 9.3.7 Market Forecast (2026-2034)
  • 9.4 Kyushu-Okinawa Region
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2020-2025)
    • 9.4.3 Market Breakup by Type
    • 9.4.4 Market Breakup by Location of Testing
    • 9.4.5 Market Breakup by Application
    • 9.4.6 Key Players
    • 9.4.7 Market Forecast (2026-2034)
  • 9.5 Tohoku Region
    • 9.5.1 Overview
    • 9.5.2 Historical and Current Market Trends (2020-2025)
    • 9.5.3 Market Breakup by Type
    • 9.5.4 Market Breakup by Location of Testing
    • 9.5.5 Market Breakup by Application
    • 9.5.6 Key Players
    • 9.5.7 Market Forecast (2026-2034)
  • 9.6 Chugoku Region
    • 9.6.1 Overview
    • 9.6.2 Historical and Current Market Trends (2020-2025)
    • 9.6.3 Market Breakup by Type
    • 9.6.4 Market Breakup by Location of Testing
    • 9.6.5 Market Breakup by Application
    • 9.6.6 Key Players
    • 9.6.7 Market Forecast (2026-2034)
  • 9.7 Hokkaido Region
    • 9.7.1 Overview
    • 9.7.2 Historical and Current Market Trends (2020-2025)
    • 9.7.3 Market Breakup by Type
    • 9.7.4 Market Breakup by Location of Testing
    • 9.7.5 Market Breakup by Application
    • 9.7.6 Key Players
    • 9.7.7 Market Forecast (2026-2034)
  • 9.8 Shikoku Region
    • 9.8.1 Overview
    • 9.8.2 Historical and Current Market Trends (2020-2025)
    • 9.8.3 Market Breakup by Type
    • 9.8.4 Market Breakup by Location of Testing
    • 9.8.5 Market Breakup by Application
    • 9.8.6 Key Players
    • 9.8.7 Market Forecast (2026-2034)

10 Japan Cardiac Biomarkers Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Services Offered
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Services Offered
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Services Offered
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Services Offered
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Services Offered
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Cardiac Biomarkers Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix